Clinical trial · Observational
DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701
Natural Killer Cell KIR and HLA Genotypes May Predict Response to Antibody Therapy in Follicular Lymphoma
NCT01057459CI-TRIAL-00028297completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research trial studies deoxyribonucleic acid (DNA) analysis in predicting response to antibody therapy in patients with follicular lymphoma treated on clinical trials Cancer and Leukemia Group B (CALGB)-50402 or CALGB-50701. Studying samples of blood from patients with follicular lymphoma in the laboratory may help doctors predict how well patients will respond to treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laboratory biomarker analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Ancillary-Correlative (biomarkers and treatment outcomes)
- description
- Genomic DNA is extracted from previously collected blood samples for KIR and HLA genotyping and polymorphism analysis.
- interventionNames
- Other: laboratory biomarker analysis
Primary outcomes (1)
- measure
- overall response
- timeFrame
- Baseline
Secondary outcomes (2)
- measure
- Progression-free survival
- timeFrame
- Baseline
- measure
- Overall survival
- timeFrame
- Baseline
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Untreated follicular lymphoma * Has received rituximab-containing monoclonal antibody therapy on CALGB-50402 or CALGB-50701 * Patients have previously provided informed consent allowing correlative studies on genomic DNA
References
Publications (0)
Data not yet available
No reference posted for this study.